Companies / VTRS vs BMY
VTRS vs BMY: Viatris and Bristol Myers Squibb
Viatris (VTRS) reported $14.3B in revenue against a -24.6% net margin, while Bristol Myers Squibb (BMY) reported $48.2B at a 14.6% net margin, most recently.
| Metric | VTRS | BMY |
|---|---|---|
| Revenue | $14.3B | $48.2B |
| Net Income | $-3.5B | $7.1B |
| Gross Margin | 35.1% | 71.1% |
| Operating Margin | -18.6% | 19.4% |
| EPS (Diluted) | $-3.00 | $3.46 |
| Free Cash Flow | $1.9B | $12.8B |
| Total Debt | $14.4B | $47.1B |
| P/E Ratio | n/m | 15.6× |
| P/B Ratio | n/m | n/m |
| Stock Price | $19.00 | $63.16 |
Free: last 5 years
| Fiscal year | FY2018 🔒 | FY2019 🔒 | FY2020 🔒 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| VTRS Revenue | ••••• | ••••• | ••••• | $17.9B | $16.3B | $15.4B | $14.7B | $14.3B |
| BMY Revenue | ••••• | ••••• | ••••• | $46.4B | $46.2B | $45.0B | $48.3B | $48.2B |